Exelixis
NASDAQ: EXELSan Francisco Bay Area, US · Founded 1994 · 1,588 employees on LinkedIn · 1 known investors
Exelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
Investors · 1
Founder mafia
The Exelixis mafia →9 people who came through Exelixis went on to found or lead other companies.
Richard HeymanSr. Vice PresidentFounded Aragon Pharmaceuticals +1Ben BurleyResearch ScientistFounded Vistapath +1Harrison YoonAssociate DirectorFounded Cacultured +1Kristine BallVP FinanceFounded Soteria Biotherapeutics +1Angie YouDirector, Business DevelopmentFounded Architect TherapeuticsJen HerbachDirector of MarketingFounded Adventris PharmaceuticalsMark Taegon BaikSenior ScientistFounded Arum TherapeuticsSang Hoon LeeSenior Scientist IIFounded ABL Bio Venture CapitalMarc RogersIon Channel Assay DevelopmentFounded Metrion Biosciences
Competitors · 2
by search overlapBioworld175 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
ADP157 shared keywordsADP provides cloud-based human capital management solutions that integrate payroll, HR, talent management, time and attendance, tax, and benefits administration for businesses globally. The company serves as a comprehensive provider of HCM software and business outsourcing services with analytics and compliance expertise.
Companies competing with Exelixis for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law | Press Releases | daily-tribune.comdaily-tribune.com · Aug 2026
Exelixis Stock Price | EXEL Stock Quote, News, and History | Markets Insidermarkets.businessinsider.com · Aug 2026Frequently asked questions
- What does Exelixis do?
- Exelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
- Who are Exelixis's investors?
- Exelixis's investors include Atlas Venture.
- Where is Exelixis headquartered?
- Exelixis is headquartered in San Francisco Bay Area, US.